Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacodynamics of Tropicamide + Phenylephrine Eye Drop Solution
Details : Tropicamide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Mydriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 20, 2025
Lead Product(s) : Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Chardan Healthcare
Deal Size : $1.3 million
Deal Type : Public Offering
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering
Details : The Company intends to use the net proceeds for the commercialization activities for Mydcombi, the first and only FDA-approved fixed dose combination ophthalmic spray for pupil dilation.
Product Name : Mydcombi
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 25, 2024
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Chardan Healthcare
Deal Size : $1.3 million
Deal Type : Public Offering
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Provides Update on Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Details : Mydcombi is FDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation
Details : Tropicamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Mydriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 22, 2024
Lead Product(s) : Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mydcombi is Eyenovia's USFDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 08, 2023
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mydcombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
Details : Mydcombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Avenue Venture Opportunities Fund
Deal Size : Undisclosed
Deal Type : Financing
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Details : The financing is intended to support manufacturing in anticipation of a MydCombi (tropicamide) launch and clinical supply for ongoing programs. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis and myopia...
Product Name : Mydcombi
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Avenue Venture Opportunities Fund
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Sundets Ögonläkare
Deal Size : Inapplicable
Deal Type : Inapplicable
Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera
Details : Mydriacyl (Tropicamide) is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Glaucoma.
Product Name : Mydriacyl
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2022
Lead Product(s) : Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Sundets Ögonläkare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Wearing-Off Period of Pharmacological Dilation and Anisocoria
Details : Tropicamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anisocoria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable